Strike Three As Novartis’s Ilaris Swings And Misses In Lung Cancer

Anti-Inflammatory Drug Fails In A Third Setting

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The final Phase III readout for Ilaris (canakinumab) in NSCLC, this time in the adjuvant setting, missed the primary endpoint. One more lung cancer trial is under way, a Phase II neoadjuvant study.

Target shot opportunity dartboard performance
The third Phase III miss for Ilaris in NSCLC is in the adjuvant setting • Source: Shutterstock

Novartis AG has long held out hope that its anti-inflammatory drug Ilaris (canakinumab) would be an effective treatment for non-small cell lung cancer (NSCLC), but three Phase III clinical trials have now proved the company wrong. The big pharma announced on 15 August that the interleukin-1beta (IL-1β) inhibitor did not meet the primary endpoint of disease-free survival (DFS) versus placebo in the Phase III CANOPY-A trial testing the biologic as an adjuvant therapy.

Ilaris previously missed the primary endpoint of overall survival (OS) in the Phase III CANOPY-2 trial versus docetaxel chemotherapy in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D